Skip to content

Study · Measured the body's own peptide · 1990

5 results

Thymosin beta 4 is expressed in ROS 17/2.8 osteosarcoma cells in a regulated manner.

Atkinson MJ, Freeman MW, Kronenberg HM

Molecular endocrinology (Baltimore, Md.)1 Jan 1990Cited by 15 (Europe PMC)

PMID2325669 (opens in a new tab)DOI10.1210/mend-4-1-69 (opens in a new tab)PepBankPUB-02325669
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelEx vivo tissueMechanism

    Thymosin beta‑4 transcripts were detected in intact neonatal and fetal rat calvaria.

    In plain wordsIn rat skull bone tissue from newborn and fetal animals, the body's own thymosin beta‑4 transcripts were found.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableTβ4 transcripts in rat calvaria
    Study

    ratn: not reported in source

    intact neonatal and fetal rat calvaria
    Outcome group
    Gene expression · Musculoskeletal

    Source sentences

    Summary
    in intact neonatal and fetal rat calvaria.
    1 context sentence
    Summary · context
    The differential expression of mRNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelIn vitro (cells)Mechanism

    Steady state thymosin beta‑4 mRNA was severalfold higher in the osteoblast-like rat ROS 17/2.8 cells than in the less osteoblast-like ROS 25/1 cells.

    In plain wordsIn rat bone tumor cells, the body's own thymosin beta‑4 mRNA was higher in osteoblast-like cells than in less osteoblast-like cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 mRNA in ROS 17/2.8 versus ROS 25/1 cells
    Study

    ratn: not reported in source

    rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1
    Comparator
    ROS 25/1 cells
    Outcome group
    Gene expression · Musculoskeletal

    Source sentences

    Summary
    Steady state mRNA levels were severalfold higher in ROS 17/2.8 cells exhibiting an osteoblast-like phenotype, compared with the less osteoblast-like ROS 25/1.
    1 context sentence
    Summary · context
    The differential expression of mRNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03LabEndogenous levelIn vitro (cells)Mechanism

    Thymosin beta‑4 transcripts were detected in rat UMR 106 osteosarcoma cells.

    In plain wordsIn rat bone tumor cells, the body's own thymosin beta‑4 transcripts were found.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableTβ4 transcripts in UMR 106 cells
    Study

    ratn: not reported in source

    rat UMR 106 osteosarcoma cells
    Outcome group
    Gene expression · Musculoskeletal

    Source sentences

    Summary
    Thymosin beta 4 transcripts were also detected in rat UMR 106 osteosarcoma cells
    1 context sentence
    Summary · context
    The differential expression of mRNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04LabEndogenous levelIn vitro (cells)Mechanism

    Treatment of ROS 17/2.8 cells with dexamethasone increased thymosin beta‑4 mRNA.

    In plain wordsIn rat bone tumor cells, dexamethasone raised the level of the body's own thymosin beta‑4 mRNA.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTβ4 mRNA after dexamethasone
    Study

    ratn: not reported in source

    rat ROS 17/2.8 osteosarcoma cells
    Outcome group
    Gene expression · Musculoskeletal

    Source sentences

    Summary
    Treatment of ROS 17/2.8 cells with dexamethasone increased
    1 context sentence
    Summary · context
    The differential expression of mRNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  5. 05LabEndogenous levelIn vitro (cells)Mechanism

    Addition of 1,25-dihydroxyvitamin D3 to ROS 17/2.8 cells decreased thymosin beta‑4 mRNA.

    In plain wordsIn rat bone tumor cells, 1,25-dihydroxyvitamin D3 lowered the level of the body's own thymosin beta‑4 mRNA.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTβ4 mRNA after 1,25-dihydroxyvitamin D3
    Study

    ratn: not reported in source

    rat ROS 17/2.8 osteosarcoma cells
    Outcome group
    Gene expression · Musculoskeletal

    Source sentences

    Summary
    while addition of 1,25-dihydroxyvitamin D3 decreased thymosin beta 4 mRNA.
    1 context sentence
    Summary · context
    The differential expression of mRNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.